Imatinib mesylate-induced acute hepatitis in a patient treated for gastrointestinal stromal tumour

被引：25

作者：

Pariente, Alexandre ^{[1
]}

Etcharry, Francine

Cales, Valerie

Laborde, Yves

Ferrari, Sylvie

Biour, Michel

机构：

[1] Ctr Hosp, Unite HGE, F-64046 Pau, France

[2] Ctr Hosp, Unite Hepatogastroenterol, Pau, France

[3] Ctr Hosp, Lab Anat & Cytol Pathol, Pau, France

[4] Ctr Hosp, Serv Chirurg Viscerale, Pau, France

[5] Hop St Antoine, Ctr Natl Pharmacovigilance, F-75571 Paris, France

来源：

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY | 2006年 / 18卷 / 07期

关键词：

drug-induced liver injury; hepatotoxicity; GIST; imatinib;

D O I：

10.1097/01.meg.0000216941.42306.0e

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

We report the first case of hepatocellular injury occurring in a patient treated for metastatic gastrointestinal stromal tumour (GIST) with imatinib mesylate, with two positive rechallenges including one with 2.5% of the current therapeutic dosage. The patient could be treated later with sunitinib without liver toxicity. Grade 3-4 liver toxicity could occur in one out of 40 treated patients with imatinib for GIST, and fatalities have been reported. Regular monitoring of liver function tests is essential in patients treated with imatinib.

引用

页码：785 / 787

页数：3

共 12 条

[1]

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors [J].

Demetri, GD ;

von Mehren, M ;

Blanke, CD ;

Van den Abbeele, AD ;

Eisenberg, B ;

Roberts, PJ ;

Heinrich, MC ;

Tuveson, DA ;

Singer, S ;

Janicek, M ;

Fletcher, JA ;

Silverman, SG ;

Silberman, SL ;

Capdeville, R ;

Kiese, B ;

Peng, B ;

Dimitrijevic, S ;

Druker, BJ ;

Corless, C ;

Fletcher, CDM ;

Joensuu, H .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (07) :472-480

[2]

Histological features of acute hepatitis after imatinib mesylate treatment [J].

James, C ;

Trouette, H ;

Marit, G ;

Cony-Makhoul, P ;

Mahon, FX .

LEUKEMIA, 2003, 17 (05) :978-979

[3]

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. [J].

Kantarjian, H ;

Sawyers, C ;

Hochhaus, A ;

Guilhot, F ;

Schiffer, C ;

Gambacorti-Passerini, C ;

Niederwieser, D ;

Resta, D ;

Capdeville, R ;

Zoellner, U ;

Talpaz, M ;

Druker, B .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (09) :645-652

[4]

Fatal hepatic necrosis following imatinib mesylate therapy [J].

Lin, NU ;

Sarantopoulos, S ;

Stone, JR ;

Galinsky, I ;

Stone, RM ;

Deangelo, DJ ;

Soiffer, RJ .

BLOOD, 2003, 102 (09) :3455-3456

[5]

Imatinib mesylate-induced hepato-toxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral hepatitis [J].

Ohyashiki, K ;

Kuriyama, Y ;

Nakajima, A ;

Tauchi, T ;

Ito, Y ;

Miyazawa, K ;

Kimura, Y ;

Serizawa, H ;

Ebihara, Y .

LEUKEMIA, 2002, 16 (10) :2160-2161

[6]

Clinical pharmacokinetics of imatinib [J].

Peng, B ;

Lloyd, P ;

Schran, H .

CLINICAL PHARMACOKINETICS, 2005, 44 (09) :879-894

[7]

Imatinib mesylate-induced acute cytolytic hepatitis [J].

Rocca, P ;

El Jastimi, S ;

Troncy, J ;

Scoazec, JY ;

Boucher, A ;

Vial, T ;

Trepo, C ;

Zoulim, F .

GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 2004, 28 (10) :918-919

[8]

METHYLDOPA HEPATITIS - REPORT OF 6 CASES AND REVIEW OF LITERATURE [J].

RODMAN, JS ;

DEUTSCH, DJ ;

GUTMAN, SI .

AMERICAN JOURNAL OF MEDICINE, 1976, 60 (07) :941-948

[9]

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study [J].

Sawyers, CL ;

Hochhaus, A ;

Feldman, E ;

Goldman, JM ;

Miller, CB ;

Ottmann, OG ;

Schiffer, CA ;

Talpaz, M ;

Guilhot, F ;

Deininger, MWN ;

Fischer, T ;

O'Brien, SG ;

Stone, RM ;

Gambacorti-Passerini, CB ;

Russell, NH ;

Reiffers, JJ ;

Shea, TC ;

Chapuis, B ;

Coutre, S ;

Tura, S ;

Morra, E ;

Larson, RA ;

Saven, A ;

Peschel, C ;

Gratwohl, A ;

Mandelli, F ;

Ben-Am, M ;

Gathmann, I ;

Capdeville, R ;

Paquette, RL ;

Druker, BJ .

BLOOD, 2002, 99 (10) :3530-3539

[10]

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study [J].

Talpaz, M ;

Silver, RT ;

Druker, BJ ;

Goldman, JM ;

Gambacorti-Passerini, C ;

Guilhot, F ;

Schiffer, CA ;

Fischer, T ;

Deininger, MWN ;

Lennard, AL ;

Hochhaus, A ;

Ottmann, OG ;

Gratwohl, A ;

Baccarani, M ;

Stone, R ;

Tura, S ;

Mahon, FX ;

Fernandes-Reese, S ;

Gathmann, I ;

Capdeville, R ;

Kantarjian, HM ;

Sawyers, CL .

BLOOD, 2002, 99 (06) :1928-1937

← 1 2 →